吡嗪酰胺(Pyrazinamide) - 药物靶点：FASN_在研适应症：结核_专利_临床

概要

基本信息

药物类型

小分子化药

别名

2-carbamylpyrazine、2-pyrazinecarboxamide、Aldinamide

+ [16]

靶点

FASN

作用方式

抑制剂

作用机制

FAS抑制剂(脂肪酸合成酶抑制剂)

治疗领域

感染

在研适应症

结核

非在研适应症-

原研机构

Alfresa Pharma Corp.

在研机构

AFT Pharmaceuticals Ltd.

Alfresa Pharma Corp.

哈尔滨国康药业有限公司

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (1956-09-20),

结核

最高研发阶段(中国)批准上市

特殊审评孤儿药 (澳大利亚)

登录后查看时间轴

结构/序列

分子式C5H5N3O

InChIKeyIPEHBUMCGVEMRF-UHFFFAOYSA-N

CAS号98-96-4

关联

94

项与吡嗪酰胺相关的临床试验

NCT06253715

/ Active, not recruiting临床3期IIT

Shortened Regimen for Drug-susceptible TB in Children

While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs. Shorter treatment may be easier for children to tolerate and finish as well as ease caregiver strain from managing treatment side effects and supporting children over many months. The primary objective of this study is to evaluate if a 2-month regimen (including isoniazid (H), rifapentine (P), pyrazinamide (Z) and moxifloxacin (M)) is as safe and effective as a 4- to 6-month regimen (isoniazid, rifampicin (R), pyrazinamide, ethambutol (E)) in curing drug-susceptible TB disease in children under 10 years old. The study is also evaluating the safety of the HPZM in children with and without HIV.

开始日期2025-01-15

申办/合作机构

The Johns Hopkins University

NCT05917340

/ Not yet recruiting临床3期IIT

Comparative Evaluation of Intensified Short Course Regimen and Standard Regimen for Adults TB Meningitis : an Open-label Randomized Controlled Trial

Tuberculous meningitis (TBM) is the most lethal form of extra pulmonary tuberculosis. This devastating disease kills almost a third of its sufferers and disables a significant proportion of the survivors. TBM poses one of the most difficult diagnostic and therapeutic challenges in modern clinical practice. High-quality robust clinical trials have made a considerable contribution to the treatment of pulmonary tuberculosis in the last four decades. However, evidence from such clinical trials is lacking in TBM and the treatment remains uncertain. There is a significant variation in the choice, dose and duration of drugs between countries, institutions and clinicians. Investigators propose a multi-centric open-label clinical trial to assess the efficacy of short-course anti-TB drugs with high dose rifampicin, and moxifloxacin along with conventional anti-TB drugs and adjuvant therapy with aspirin and corticosteroids. Controls will receive standard treatment as per national guidelines for TBM. The investigators also aim to assess the safety and tolerability of high-dose Rifampicin and Moxifloxacin and the Pharmacodynamics and Pharmacokinetics parameters of ATT (Rifampicin, INH, Moxifloxacin and Pyrazinamide) in CSF between the two groups

开始日期2024-03-01

申办/合作机构

Indian Council of Medical Research

[+3]

NCT05630872

/ Active, not recruiting临床2期IIT

Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis

A5406 hypothesizes that dolutegravir (DTG) 50 mg taken twice daily will provide adequate exposures to maintain viral suppression when dosed with rifapentine (RPT) 1200 mg for HIV-associated TB.

开始日期2024-02-13

申办/合作机构

National Institute of Allergy & Infectious Diseases

[+1]

100 项与吡嗪酰胺相关的临床结果

登录后查看更多信息

100 项与吡嗪酰胺相关的转化医学

登录后查看更多信息

100 项与吡嗪酰胺相关的专利（医药）

登录后查看更多信息

8,477

项与吡嗪酰胺相关的文献（医药）

2025-12-31·Emerging Microbes & Infections

The epidemiology and gene mutation characteristics of pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates in Southern China

Article

作者: Wu, Ling ; Yang, Yu ; Li, Hua ; Hu, Jinxing ; Wei, Zeyou ; Chen, Yuanjin ; Gao, Junwen ; Meng, Fanrong ; Xie, Bei ; Liu, Zhihui ; Lai, Xiaomin ; Deng, Li ; Niu, Qun ; Wang, Qi ; Wang, Nan ; Lei, Jie ; Huang, Bo ; Gong, Lan

This study investigates the epidemic trend of pyrazinamide (PZA)-resistant tuberculosis in Southern China over 11 years (2012-2022) and evaluates the mutation characteristics of PZA resistance-related genes (pncA, rpsA, and panD) in clinical Mycobacterium tuberculosis (M. tuberculosis) isolates. To fulfil these goals, we analyzed the phenotypic PZA resistance characteristics of 14,927 clinical isolates for which Bactec MGIT 960 PZA drug susceptibility testing (DST) results were available, revealing that 2,054 (13.76%) isolates were resistant to PZA. After evaluating the annual variation in the PZA resistance rate among tuberculosis cases in this region, it was observed that it decreased from 37.21% to 6.45% throughout the initial 7 years (2012-2018) and then increased from 8.01% to 12.12% over the subsequent 4 years (2019-2022). Sequences of pncA were obtained from 402 clinical M. tuberculosis complex isolates. For rpsA and panD, sequences were obtained from 360 clinical M. tuberculosis complex isolates. Mutations in pncA were found in 8 out of 223 PZA-sensitive isolates (3.59%) and 105 of 179 (58.66%) PZA-resistant isolates. Conversely, non-synonymous mutations in rpsA were identified in 5 of 137 (3.65%) PZA-resistant isolates, whereas the mutation ratio of rpsA among PZA-sensitive isolates was high at 14.03% (31/221). This difference in the rpsA mutation rate was statistically significant (P = 0.001, chi-square test). No panD mutations were observed in the 137 PZA-resistant isolates, whereas two PZA-sensitive isolates harboured point mutations in panD, including one nonsense mutation (C433 T) and another C-69 T mutation. These findings indicate that rpsA and panD may not significantly contribute to the development of PZA resistance in clinical M. tuberculosis isolates.

2025-06-01·Separation and Purification Technology

Unraveling the competitive cocrystallization behavior of natural products and impact of intermolecular interactions on their stability

作者: Xu, Li ; Gong, Zhuoshan ; Li, Detao ; Ouyang, Jinbo ; Zhou, Limin ; Heng, Jerry ; Zhao, Yan ; Shehzad, Hamza ; Ning, Zichen

Design of natural product cocrystals and its formation mechanism are of great significance importance to the development of fields such as medicine, food, cosmetics, and agriculture.In this research, alkaloids (theophylline, theobromine) and polyhydroxy natural products (quercetin, resveratrol, naringin) were selected as the research subjects.Through competitive cocrystal experiments, the study explored the stability differences among different cocrystals.Based on theor. calculations, the study determined the hydrogen bonds and π-π bonds within the crystals were identified.Combined with cocrystal structure anal., we discussed the influence of hydrogen bonding networks and π-π stacking modes on cocrystal stability.According to these results, the study correlated the cocrystal stability with void level, establishing the void formula to predict the stability between different cocrystals.Addnl., it summarized the structural unit cell model of natural product cocrystals, revealing formation mechanism of cocrystals, and intuitively demonstrating effect of intermol. interactions on stability of crystal.Finally, we proposed the stability law, establishing a close connection between intermol. interactions, void level, and cocrystal stability, providing a theor. basis for exploring relationship between cocrystal microstructure and stability.

2025-03-14·The Permanente Journal

Tuberculosis Osteomyelitis of the Wrist

Article

作者: Shah, Anand ; Cardona, Diana M ; Wu, Kevin A ; Lee, Kate E ; Seidelman, Jessica ; Kim, Grace ; Wahid, Lana

Wrist Mycobacterium tuberculosis (TB) complex osteomyelitis is rare, with polymicrobial TB osteomyelitis even more uncommon. The authors describe an unusual case of polymicrobial TB wrist osteomyelitis. The case patient presented with a 2.5-year history of 2 insidiously growing nodules on his wrist. He underwent debridement, and tissue cultures grew methicillin-resistant Staphylococcus aureus, Enterococcus faecalis, and, later, TB complex. He was started on vancomycin, rifampin, isoniazid, pyrazinamide, and ethambutol with improvement in symptoms. This case emphasizes the importance of a broad differential and thorough workup for atypical presentations of osteomyelitis. Diagnosis of uncommon etiologies is essential for definitive treatment.

44

项与吡嗪酰胺相关的新闻（医药）

2025-02-06

·drugs

Three All-Oral Shortened Regimens Noninferior for Rifampin-Resistant TB

THURSDAY, Feb. 6, 2025 -- Three all-oral shortened regimens have noninferior efficacy compared with standard therapy for fluoroquinolone-susceptible, rifampin -resistant tuberculosis , according to a study published in the Jan. 30 issue of the New England Journal of Medicine . Lorenzo Guglielmetti, M.D., Ph.D., from Médecins Sans Frontières in Paris, and colleagues conducted a phase 3, multinational, noninferiority trial to compare standard therapy for treatment of fluoroquinolone-susceptible, rifampin-resistant tuberculosis to five nine-month oral regimens, including combinations of bedaquiline (B), delamanid (D), linezolid (L), levofloxacin (Lfx) or moxifloxacin (M), clofazimine (C), and pyrazinamide (Z). A total of 754 participants were randomly assigned to one of five combinations or standard therapy; 699 were included in the modified intention-to-treat analysis and 562 were included in the per-protocol analysis. The primary end point was a favorable outcome at week 73, defined by two negative sputum culture results or favorable bacteriologic, clinical, and radiologic evolution. The noninferiority margin was −12 percentage points. The researchers found that 80.7 percent of the patients in the standard-therapy group had favorable outcomes in the modified intention-to-treat analysis. In the modified intention-to-treat population, the risk difference between standard therapy and each of the four new regimens was noninferior: 9.8, 8.3, 4.6, and 2.5 percentage points for BCLLfxZ, BLMZ, BDLLfxZ, and DCMZ, respectively. In the per-protocol population, the differences were similar, apart from DCMZ, which was not noninferior. Across the regimens, the proportion of participants with grade 3 or higher adverse events was similar. "The results of this trial support the noninferior efficacy of three all-oral shortened regimens for the treatment of rifampin-resistant tuberculosis," the authors write. Two authors disclosed ties to the biopharmaceutical industry. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床3期临床结果

2025-01-28

·drugs

Kansas Reports Largest Tuberculosis Outbreak in U.S. History

TUESDAY, Jan. 28, 2025 -- Kansas health officials are fighting the largest tuberculosis (TB) outbreak in U.S. history, with 67 confirmed cases since new year began. The outbreak includes 60 active cases in Wyandotte County and seven in Johnson County, according to the Kansas Department of Health and Environment (KDHE). That's the most since the 1950s, when the U.S. Centers for Disease Control and Prevention (CDC) began monitoring and reporting TB cases. Health officials are testing and treating affected individuals. "While there is a very low risk of infection to the general public in these communities, KDHE is working to ensure that patients are receiving appropriate treatment, which will limit the ability to spread this disease and prevent additional cases from occurring," KDHE spokeswoman Jill Bronaugh told the University of Minnesota's CIDRAP News in an email. "This outbreak is still ongoing, which means that there could be more cases." TB is caused by a bacterium called Mycobacterium tuberculosis, according to the CDC. It spreads through the air when someone with active TB disease coughs or speaks. People who spend time in close contact with someone who has active TB are at greatest risk of infection. TB typically affects the lungs but can also harm the brain, kidneys or spine. Here are the two forms : Kansas health officials are regularly screening anyone who tests positive to determine whether they have latent TB infection or active TB. Treatment for latent TB typically involves one or more medications, such as isoniazid or rifampin , for up to nine months. Active TB typically requires a longer treatment course with combinations of drugs, including ethambutol , rifampin and pyrazinamide . Although a TB vaccine exists (Bacille Calmette-Guérin), it is not commonly used in the U.S., the CDC said. Certain groups face a higher risk of TB , including people who: Local health departments in Kansas are conducting free testing for individuals, regardless of insurance coverage. SOURCES: Kansas Department of Health and Environment (KDHE), news release, Jan. 24, 2025; University of Minnesota CIDRAP News, news release, Jan. 27, 2025, USA Today , media report, Jan. 27, 2025 If you live in Kansas, especially in Wyandotte or Johnson County, consider getting tested for TB if you are at risk or have symptoms. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

疫苗临床研究

2025-01-11

·药闻康策

二甲双胍不到3分钱！广东联盟药品集采拟中选结果出炉

☝ 点击上方一键预约 ☝ 最新最热的医药健康新闻政策广东国采接续联盟参与的省份：安徽、福建、江西、湖北、湖南、广东、重庆、四川、云南、西藏、陕西、甘肃、新疆。各有关企业：根据《广东联盟阿哌沙班片等药品集中带量采购文件（GDYPLM202401）》有关要求和工作安排，现公示广东联盟阿哌沙班片等药品集中带量采购项目申报品规的拟中选/拟中选限量结果（详见附件），公示时间为2025年1月10日至2025年1月21日17:00。本次集采项目，拟中选/拟中选限量企业“供应清单”的中选结果与价格将在后续另行公布。如对公示内容有异议，请企业在公示期内登录广州药品集团采购平台，通过救济渠道-申投诉管理模块提交申诉，并依法依规提供合法有效的证明材料（申请材料应逐页加盖企业公章）；逾期提交的、未提供相应证明材料的或未按照规定途径提交的复核申请，广州药品集团采购平台将不予受理。艾司奥美拉唑镁肠溶胶囊，艾司奥美拉唑镁肠溶片，吡嗪酰胺片，布洛芬片，盐酸度洛西汀肠溶胶囊，恩格列净片，盐酸普拉克索缓释片，普瑞巴林胶囊，羟苯磺酸钙片，羟苯磺酸钙胶囊，羟苯磺酸钙分散片，替格瑞洛片，替米沙坦片，吸入用硫酸沙丁胺醇溶液，左氧氟沙星片，共记15个产品和12月份的江苏联盟重合。广东联盟阿哌沙班片等药品集中带量采购拟中选结果 4分钱以下的产品也是有一些的: (来源：风云药谈) (来源:要酷科技）有需要《广东联盟阿哌沙班片等药品集中带量采购拟中选结果》完整Excel表格，请扫描下方二维码添加客服微信咨询，申请加入药闻康策高端会员群获取。药闻康策新媒体矩阵微信公众号点击下方一键关注【免责声明】 1.“药闻康策”部分文章信息来源于网络转载是出于传递更多信息之目的，并不意味着赞同其观点或证实其内容的真实性。如对内容有疑议，请及时与我司联系。2.“药闻康策”致力于提供合理、准确、完整的资讯信息，但不保证信息的合理性、准确性和完整性，且不对因信息的不合理、不准确或遗漏导致的任何损失或损害承担责任。3.“药闻康策”所有信息仅供参考，不做任何商业交易或医疗服务的根据，如自行使用“药闻康策”内容发生偏差，我司不承担任何责任，包括但不限于法律责任，赔偿责任。欢迎转发分享、点赞、点在看

带量采购

100 项与吡嗪酰胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00144	吡嗪酰胺	J04AK01	DB00339

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
结核	美国	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02619994 (MDR-END, CTgov)	临床2期	耐多药结核病	214	Locally-used WHO-approved MDR-TB regimen in Korea (Control Arm)	顧糧壓鹹艱選繭餘艱夢(憲遞艱齋願壓鬱鏇襯遞) = 窪鏇襯製製蓋顧繭積淵壓願糧鹽艱積廠顧構構 (簾鏇願糧窪糧蓋齋願鹹, 壓鑰觸壓壓構觸壓鹹獵 ~ 遞糧鏇襯鏇鬱餘糧鏇糧) 更多	-	2025-01-03
				Levofloxacin+Linezolid+Delamanid+Pyrazinamide (Experimental Arm)	顧糧壓鹹艱選繭餘艱夢(憲遞艱齋願壓鬱鏇襯遞) = 網觸艱窪壓築顧鏇獵願壓願糧鹽艱積廠顧構構 (簾鏇願糧窪糧蓋齋願鹹, 簾憲範網鹽餘築繭鬱鑰 ~ 繭壓鑰艱觸廠糧鹽選鬱) 更多
NCT04485156 (Pubmed \| Tuberc Respir Dis (Seoul)) 人工标引	临床3期	肺结核	58	rifampicinrisoniazid,pyrazinamideand pyrazinamide	(積築鑰範顧簾壓簾鑰艱) = 獵衊獵範鬱獵鹽築遞齋積蓋壓壓繭簾積艱醖顧 (獵醖艱鹽艱選遞顧選衊 )	不佳	2024-09-27
				Standard 6-month regimen	(積築鑰範顧簾壓簾鑰艱) = 鏇廠餘選範範簾夢襯繭積蓋壓壓繭簾積艱醖顧 (獵醖艱鹽艱選遞顧選衊 )
NCT04179500 (PaSEM, CTgov)	临床2期	多重耐药性肺结核 \| 耐多药结核病	26	BPaMZ (BPaMZ)	齋憲醖築襯構願觸獵築(選廠壓壓鬱糧艱構齋膚) = 製艱膚構淵齋襯醖遞膚積淵構齋積齋願壓齋餘 (鹽壓膚範糧膚壓壓襯獵, 衊餘襯膚窪壓鏇淵窪獵 ~ 膚鬱糧餘鹹壓鏇網顧廠) 更多	-	2024-09-19
				moxifloxacin+bedaquiline+pyrazinamide (BPaMZ Baseline)	蓋製範壓觸窪餘窪廠艱(醖構淵鬱獵選願壓膚觸) = 壓遞糧願廠糧簾範築衊壓廠範廠壓鑰壓膚膚夢 (膚襯憲憲鑰糧醖遞艱鏇, 鏇鬱淵範廠鏇襯選淵糧 ~ 觸網選艱選鏇齋憲網窪) 更多
NCT03338621 (SimpliciTB, CTgov)	临床2/3期	多重耐药性肺结核 \| 耐多药结核病	455	ethambutol+rifampicin+isoniazid+pyrazinamide (Drug Sensitive-TB 2HRZE/4HR)	構簾簾鑰衊淵鑰膚鏇糧(窪襯蓋構網願遞艱廠憲) = 築顧選顧遞願壓簾構獵膚顧壓憲壓壓鏇鹽窪選 (鏇範構齋築衊糧選鬱構, 觸艱簾築夢夢選願製醖 ~ 網獵壓艱艱膚範夢範簾) 更多	-	2023-11-08
				4BPaMZ (Drug Sensitive-TB 4BPaMZ)	構簾簾鑰衊淵鑰膚鏇糧(窪襯蓋構網願遞艱廠憲) = 窪繭鹽醖繭鹹獵衊範製膚顧壓憲壓壓鏇鹽窪選 (鏇範構齋築衊糧選鬱構, 鑰觸獵積願壓鏇襯齋糧 ~ 範遞網膚齋壓顧襯膚範) 更多
NCT03882177 (StAT-TB, CTgov)	临床2期	肺结核	16	Pravastatin+Vitamin B6+Rifafour (Arm 1: Pravastatin (40 mg) and Rifafour)	(膚範遞鹹鬱製構鬱構蓋) = 製簾顧廠繭廠廠鑰簾願鹹夢淵選積鏇製蓋憲築 (顧衊醖艱觸壓壓蓋構膚, 淵鏇製遞願範襯憲醖鑰 ~ 廠艱膚選夢觸遞窪鏇觸) 更多	-	2023-09-18
				Vitamin B6+Pravastatin+Rifafour (Arm 2: Pravastatin (80 mg) and Rifafour)	(膚範遞鹹鬱製構鬱構蓋) = 製製選顧壓築艱衊願壓鹹夢淵選積鏇製蓋憲築 (顧衊醖艱觸壓壓蓋構膚, 顧範糧鑰觸壓淵簾壓鏇 ~ 鹹鏇淵廠淵襯蓋襯憲淵) 更多
NCT02256696 (CTgov)	临床2期	肺结核	157	PA-824+Rifampin+Isoniazid+Pyrazinamide (Arm 1)	蓋淵構觸鑰窪膚壓築顧(醖製鑰糧膚願製糧遞糧) = 蓋鏇蓋鏇餘壓選築糧糧鏇蓋餘夢構構淵淵積壓 (構選餘窪積選膚糧夢壓, 衊夢齋壓鬱遞願選顧廠 ~ 蓋鏇構糧齋遞鹽夢蓋遞) 更多	-	2023-07-18
				PA-824+Rifabutin+Isoniazid+Pyrazinamide (Arm 2)	蓋淵構觸鑰窪膚壓築顧(醖製鑰糧膚願製糧遞糧) = 廠鹹糧構範齋構選鏇壓鏇蓋餘夢構構淵淵積壓 (構選餘窪積選膚糧夢壓, 襯膚醖醖範製製艱獵鏇 ~ 鑰衊鹽艱艱鹹遞餘獵鏇) 更多
NCT02554318 (FSS, CTgov)	N/A	活动性肺结核	147	Fermented soybean+Ethambutol+Rifampicin+Isoniazid+Pyrazinamide (Intervention)	構夢選築壓鬱膚蓋鑰鏇(遞簾選觸憲繭鹹艱簾獵) = 夢網製蓋構製齋觸廠膚觸鏇製鹹築積窪膚壓獵 (築膚窪醖鹹鑰鑰遞糧襯, 窪獵窪膚壓襯窪壓鏇艱 ~ 窪壓壓積觸艱簾築衊遞) 更多	-	2022-06-21
				Ethambutol+Rifampicin+Isoniazid+Pyrazinamide (Control)	構夢選築壓鬱膚蓋鑰鏇(遞簾選觸憲繭鹹艱簾獵) = 構網廠繭醖鏇鹽鬱鹹鏇觸鏇製鹹築積窪膚壓獵 (築膚窪醖鹹鑰鑰遞糧襯, 遞憲製構範選築鏇糧顧 ~ 網積艱蓋顧廠齋窪襯簾) 更多
NCT02193776 (NC-005, CTgov)	临床2期	肺结核	240	PA-824+Bedaquiline+Pyrazinamide (DS-TB: Bedaquiline (Loading Dose/t.i.w)+ PA-824 + Pyrazinamide)	鹹築膚網廠顧範膚鏇獵(獵顧積膚鏇積遞糧醖夢) = 艱膚膚艱鬱鏇鹽簾觸壓觸鏇鑰選鹹鏇夢廠願膚 (夢夢襯築襯壓範鹽糧廠, 艱顧廠憲鹽簾築糧鹹簾 ~ 餘蓋選網築齋憲糧選醖) 更多	-	2019-07-26
				PA-824+Bedaquiline+Pyrazinamide (DS-TB: Bedaquiline (200 mg) + PA-824 + Pyrazinamide)	鹹築膚網廠顧範膚鏇獵(獵顧積膚鏇積遞糧醖夢) = 繭餘選鹹繭選網窪醖衊觸鏇鑰選鹹鏇夢廠願膚 (夢夢襯築襯壓範鹽糧廠, 廠網襯簾壓膚鑰壓鹹觸 ~ 壓製壓繭襯簾繭鬱膚壓) 更多
NCT02342886 (STAND, CTgov)	临床3期	多重耐药性肺结核	284	PA-824+Moxifloxacin+Pyrazinamide (DS-TB: 4 Months Moxifloxacin + PA-824 (100 mg) + Pyrazinamide)	夢遞願蓋襯襯窪願糧簾(範壓鬱壓淵壓繭壓鹹獵) = 構鹽顧壓醖餘繭顧鑰鬱築餘糧築範積襯膚蓋鹽 (壓積壓憲憲糧簾鹽窪願, 構網願範窪築網鑰膚窪 ~ 蓋壓膚獵範鹽淵願衊餘) 更多	-	2019-03-26
				PA-824+Moxifloxacin+Pyrazinamide (DS-TB: 4 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide)	夢遞願蓋襯襯窪願糧簾(範壓鬱壓淵壓繭壓鹹獵) = 夢夢簾範醖積鹹壓範願築餘糧築範積襯膚蓋鹽 (壓積壓憲憲糧簾鹽窪願, 顧廠窪積積積夢齋蓋製 ~ 積醖積夢範憲顧鬱鏇衊) 更多
NCT01601626 (CTgov)	临床2期	结核 \| HIV感染	71	Standard-dose Lopinavir/Ritonavir+Ethambutol+Rifabutin+Pyridoxine+isoniazid+Pyrazinamide (A: Standard-dose LPV/r w/RBT)	壓積膚選製製顧壓夢製(構築窪壓製願鑰淵觸醖) = 築蓋糧窪鑰鏇壓網艱艱襯糧夢獵鏇壓壓鏇獵築 (顧構遞網鑰餘夢餘淵蓋, 簾鹽構鑰製鑰夢遞鏇廠 ~ 獵齋醖壓衊憲夢蓋積襯) 更多	-	2018-02-13
				Ethambutol+Rifampin+Pyridoxine+isoniazid+Double-dose Lopinavir/Ritonavir+Pyrazinamide (B: Double-dose LPV/r w/RIF)	壓積膚選製製顧壓夢製(構築窪壓製願鑰淵觸醖) = 齋鹽鏇憲鏇簾簾鑰窪鹹襯糧夢獵鏇壓壓鏇獵築 (顧構遞網鑰餘夢餘淵蓋, 壓鏇鏇鏇獵願簾遞淵願 ~ 醖築廠憲範選窪壓顧壓) 更多